Doxycycline desensitization in chronic Q fever—A critical tool for the clinician
Aila Luise Caplunik-Pratsch,
Israel Potasman,
Aharon Kessel,
Alona Paz
Affiliations
Aila Luise Caplunik-Pratsch
Infectious Diseases Unit, Bnai-Zion Medical Center, Sderot Eliyahu Golomb 47, Haifa Affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
Israel Potasman
Infectious Diseases Unit, Bnai-Zion Medical Center, Sderot Eliyahu Golomb 47, Haifa Affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
Aharon Kessel
Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Sderot Eliyahu Golomb 47, Haifa Affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
Alona Paz
Infectious Diseases Unit, Bnai-Zion Medical Center, Sderot Eliyahu Golomb 47, Haifa Affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
We present the case of a 45 year old woman with acute Q fever pneumonia who progressed to the chronic phase of the disease despite azithromycin therapy. A trial of doxycycline was halted because of severe allergy and she was put on clarithromycin and later moxifloxacin. Failure of both drugs required desensitization to doxycycline with escalating doses. After two-year treatment with doxycycline-hydroxychloroquine combination, complete recovery was declared. Our case highlights the option of doxycycline desensitization when an acute allergic reaction poses an obstacle to optimal treatment.